Hemophilia C: Understanding Factor XI Deficiency

Understanding Hemophilia C (Factor XI Deficiency) Hemophilia C, also known as Factor XI deficiency, is a rare inherited blood disorder that affects the body's ability to form blood clots. While it shares the name 'hemophilia' with more common types like Hemophilia A and B, it has distinct characteristics in its inheritance pattern and severity. In healthy individuals, blood clotting is a complex process involving various protein molecules called clotting factors. There are 13 such factors, numbered I through XIII. Hemophilia C arises when there's a deficiency in Factor XI, a crucial component in this clotting cascade. What Causes Hemophilia C? Hemophilia C is caused by a mutation in the F11 gene. This gene provides the instructions for making Factor XI. The mutation prevents the body from producing sufficient amounts of this essential clotting factor. Unlike Hemophilia A and B, which are X-linked recessive disorders primarily affecting males, Hemophilia C is an autosomal recessive disease. This means the F11 gene is located on a non-sex chromosome. For an individual to develop symptoms of Hemophilia C, they must inherit two copies of the mutated F11 gene, one from each parent. Individuals who inherit only one copy are carriers and can pass the condition to their offspring without exhibiting symptoms themselves. How Rare is Hemophilia C? Hemophilia C is exceptionally rare, with estimates suggesting it affects approximately 1 in 100,000 people worldwide. However, certain populations have a higher prevalence. For instance, up to 8% of individuals of Ashkenazi Jewish descent living in Israel are estimated to have this disorder. Despite its rarity, it's important to understand its implications for those affected. Hemophilia C vs. Hemophilia A and B It's crucial to differentiate Hemophilia C from Hemophilia A and B. Hemophilia A is due to a deficiency in Factor VIII, and Hemophilia B (also known as Christmas disease) is due to a deficiency in Factor IX. Both A and B are X-linked and tend to cause more severe bleeding symptoms and affect males more frequently. Hemophilia C, being autosomal recessive, affects all genders equally. Its symptoms are often milder, and many individuals may not experience any noticeable issues until adulthood or after a significant injury or surgery. Symptoms of Hemophilia C The symptoms of Hemophilia C can vary significantly, with many individuals experiencing very mild or no symptoms at all. When symptoms do occur, they often manifest in adulthood. People with uteruses may experience more pronounced symptoms, particularly related to menstrual bleeding and childbirth. Common symptoms include: Excessive bleeding or bruising: This is often noticed after an injury, surgery, or dental procedures. Unlike Hemophilia A and B, spontaneous bleeding (bleeding without an apparent cause) is less common in Hemophilia C. Prolonged bleeding after surgery or dental work: This is a hallmark symptom, as the body struggles to form a clot effectively. Nosebleeds: Frequent or prolonged nosebleeds can occur. Heavy menstrual bleeding (menorrhagia): For individuals with uteruses, periods can be unusually long and heavy. Bleeding after childbirth: Postpartum hemorrhage can be a concern. It's important to note that some individuals may exhibit symptoms even with only one copy of the mutated gene, though this is less common. Diagnosis of Hemophilia C A diagnosis of Hemophilia C typically begins when a doctor suspects the condition based on a patient's symptoms, a family history of bleeding disorders, or unusual bleeding after a medical procedure. A hematologist, a specialist in blood disorders, will usually conduct a series of blood tests to assess: Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT): These tests measure how long it takes for blood to clot. Prolonged times can indicate a clotting factor deficiency. Factor XI Activity Level: This specific test measures the amount of functional Factor XI in the blood. Low levels confirm the deficiency. Genetic Testing: In some cases, genetic tests may be performed to identify the specific mutation in the F11 gene, confirming the diagnosis and understanding the genetic basis. Following a diagnosis, genetic counseling is often recommended, especially for individuals planning to have children, to discuss the inheritance patterns and potential risks. Treatment and Management The primary goal of treatment for Hemophilia C is to manage bleeding episodes and prevent complications. The approach depends on the severity of the deficiency and the presence of symptoms. Factor XI Concentrate: For active bleeding or before surgery, treatment may involve administering Factor XI concentrate to temporarily boost the clotting factor levels in the blood. This is typically given intravenously. Antifibrinolytic Medications: Drugs like tranexamic acid can help stabilize blood clots once they have formed, preventing them from breaking down too quickly. These are often used for managing heavy menstrual bleeding or bleeding after dental procedures. Desmopressin (DDAVP): In some cases, DDAVP may be used. It can help release stored Factor XI from tissues into the bloodstream, temporarily increasing levels. However, its effectiveness can vary. Avoiding Certain Medications: Patients are often advised to avoid medications that can interfere with blood clotting, such as aspirin and non-steroidal anti-inflammatory drugs (NSAIDs), unless specifically prescribed by their doctor. Regular monitoring by a hematologist is essential to manage the condition effectively. Prevention and Outlook Since Hemophilia C is a genetic disorder, it cannot be prevented. However, for individuals diagnosed with the condition, proactive management can significantly reduce the risk of severe bleeding and maintain a good quality of life. Understanding the condition, adhering to treatment plans, and communicating openly with healthcare providers are key. When to

In summary, timely diagnosis, evidence-based treatment, and prevention-focused care improve long-term health outcomes.